Nanoform FinlandSTU:4YL -1.45%70 Gross Margin % is 94.19% as of Mar. 2026, which is 38% above its 10-year median of 68.41. GuruFocus rates STU:4YL with a GF Score™ of 70/100 and a GF Value™ of €1.77 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 732 Biotechnology companies, Nanoform Finland ranks better than 83.33% on this metric.
The historical rank and industry rank for Nanoform Finland's Gross Margin % or its related term are showing as below:
STU:4YL'
s Gross Margin % Range Over the Past 10 Years
Min: -1130.61 Med: 68.41 Max: 91.66
Current: 89.4
During the past 10 years, the highestGross Margin % of Nanoform Finland was 91.66%. The lowest was -1130.61%. And the median was 68.41%.
STU:4YL's Gross Margin % is ranked better than 83.33% of 732
companies
in the Biotechnology industry
Industry Median: 60.91
vs STU:4YL: 89.40
Nanoform Finland had a gross margin of 94.19% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Nanoform Finland was 1.20% per year.
Nanoform Finland (STU:4YL) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nanoform Finland had a gross margin of 94.19% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Nanoform Finland Gross Margin % Related Terms
Nanoform Finland Gross Margin % Historical Data
* Premium members only.
The historical data trend for Nanoform Finland's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4YL vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Nanoform Finland's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanoform Finland Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanoform Finland's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Nanoform Finland's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nanoform Finland (STU:4YL) has a Gross Margin % of 94.19% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Nanoform Finland and its competitors. This is 38% above median its historical median of 68.41. According to the industry distribution chart, Nanoform Finland ranks #122 out of 732 companies in the Biotechnology industry, placing it in the top 16.7%.
Is Nanoform Finland's Gross Margin % too high?
Nanoform Finland's current Gross Margin % of 94.19% is 38% above median its 10-year median of 68.41. The Biotechnology industry median Gross Margin % is 60.91. Nanoform Finland's value of 94.19% is 54.6% above this industry median. Based on the distribution chart, Nanoform Finland ranks #122 out of 732 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nanoform Finland has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanoform Finland's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanoform Finland ranks #122 out of 732 companies for Gross Margin %. This places Nanoform Finland in the top 17% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Nanoform Finland's value of 94.19% is 54.6% above this benchmark. While the company's 10-year median is 68.41 vs. the industry median of 60.91, Nanoform Finland has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanoform Finland's current Gross Margin % of 94.19% is 54.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Nanoform Finland and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanoform Finland's current Gross Margin % is 94.19%, which is 38% above median its own 10-year median of 68.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoform Finland stock overvalued right now?
Based on GuruFocus' analysis, Nanoform Finland (STU:4YL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.77, compared to a current price of €0.75 — trading 57.7% below its estimated fair value. The current Gross Margin % is 94.19%, which is 38% above median its 10-year median of 68.41 and 54.6% above the Biotechnology industry median of 60.91. Nanoform Finland's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Nanoform Finland (STU:4YL), the current Gross Margin % is 94.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanoform Finland (STU:4YL) Overvalued in 2026?
Based on GuruFocus' analysis, Nanoform Finland stock appears to be undervalued.
The current stock price of €0.75 is trading 57.7% below its estimated GF Value™ of €1.77.
GuruFocus considers Nanoform Finland to be Possible Value Trap.
Key valuation signals for STU:4YL:
Gross Margin %: 94.19% (38% above median its 10-year median of 68.41)
GF Value™: €1.77 vs. price of €0.75 (57.7% below fair value)
Industry Position: 54.6% above the Biotechnology median (#122 of 732)
No single metric tells the full story. See the STU:4YL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
70GF Score
Get the complete analysis for STU:4YL
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4YL has been successfully added to your 
